Multiple cardiac assays are available to meet your point-of-care testing demands. Test cartridges are individually packaged, providing flexibility to select appropriate tests based on patient need. As many as four assays can be run simultaneously per patient sample on the Stratus CS 200 system*
Guideline Acceptable Sensitive Troponin I Assay
The cTnl assay meets the ESC/ACC Joint Committee recommendations of ≤10% CV at the 99th percentile of a normal population. The assay is used for the measurement of cardiac troponin I to aid in the diagnosis of AMI and in the risk stratification of patients with acute coronary syndromes (ACS).
D-dimer Assay (with Pulmonary Embolism Exclusion†
D-dimer is a quantitative measurement of cross-linked fibrin degradation products (D-dimer) in human citrated or heparinized plasma. The D-dimer assay is intended for use in conjunction with a non-high clinical pretest probability (PTP) assessment model to exclude pulmonary embolism (PE) disease and as an aid in the diagnosis of venous thromboembolism (VTE) [deep vein thrombosis (DVT) or PE].
CKMB Mass Assay
CKMB is for the measurement of the MB isoenzyme of creatine kinase in heparinized whole blood/plasma. CKMB measurements can be used as an aid in diagnosing acute myocardial infarction.
Myoglobin measures myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardial infarction.
NT-proBNP is a quantitative measurement of N-terminal pro-brain natriuretic peptide (NT-proBNP) in heparinized plasma. Measurements of NT-proBNP are used as an aid in the diagnosis of individuals suspected of having congestive heart failure (CHF). The test is further indicated for the risk stratification of patients with acute coronary syndrome and heart failure, resulting from left-ventricular dysfunction.
CardioPhase® hsCRP Assay
Measurement of CRP is useful for the detection and evaluation of infection, tissue injury, inflammatory disorders, and associated diseases. High-sensitivity CRP (hsCRP) measurements may be used as an independent risk marker for the identification of individuals at risk for future cardiovascular disease. Measurements of hsCRP, when used in conjunction with traditional clinical laboratory evaluation of acute coronary syndromes, may be useful as an independent marker of prognosis for recurrent events, in patients with stable coronary disease or acute coronary syndromes.
Quantitative βhCG Assay
Running STAT βhCG ensures that clinicians know of any potential pregnancies in their cardiac patients, and can recommend the most appropriate diagnostic assessments for those patients.